Blockbuster's Shadow: Pipeline Starvation and Delayed Feedback at Meridian Biopharma

Meridian Biopharma is a global pharmaceutical company with 22,000 employees, $18B in annual revenue, and a research engine spanning oncology, immunology, cardiovascular, and neuroscience. For a decade, its oncology franchise-anchored by two blockbuster checkpoint-inhibitor drugs-has generated 60% of revenue and an even larger share of profit. The company is caught in two interlocking systems structures. The first is a success-to-the-successful reinforcing loop: oncology's commercial success attracts more R&D investment, more talent, more clinical trial capacity, and more leadership attention, which produces more oncology success, which justifies still more investment. The other therapeutic areas-immunology, cardiovascular, neuroscience-receive declining shares of a growing but finite R&D budget, and their pipelines are thinning. The second structure is delayed feedback. Pharmaceutical R&D has the longest feedback delays of any industry: a molecule entering preclinical testing today may not produce clinical readout for 7-10 years and may not reach market for 12-15 years. This means the pipeline decisions being made today are based on market conditions and science that will be a decade old by the time results arrive. The delays make it nearly impossible for balancing loops (portfolio reviews, stage-gate decisions) to correct course in time-by the time a thinning pipeline is visible as a revenue gap, it is years too late to refill it organically. The combination is dangerous: the reinforcing loop concentrates investment in oncology now, while the delayed feedback means the future revenue gap from starving other areas won't be visible until it's too late to close without expensive acquisitions. Meridian is an open system exchanging with the FDA, payers, competitors, patient advocates, and capital markets-all of whom send signals that reinforce the oncology concentration. The Chief Scientific Officer has engaged a systems thinking consultant to help the R&D leadership team map the reinforcing and delayed-feedback structure, understand why the portfolio balancing loops are failing, and design interventions that protect pipeline diversity without killing the oncology engine.

Key Stakeholders

Dr. Eleanor Whitman

Chief Scientific Officer

Dr. Rajesh Kulkarni

Head of Oncology Research

Dr. Sofia Marchetti

Head of Immunology & Neuroscience Research

James Harrington

Chief Financial Officer

Dr. Marcus Adeyemi

Head of Portfolio Strategy & Systems Thinking Consultant

Learning Objectives

• Diagram the success-to-the-successful reinforcing loop linking blockbuster revenue, R&D investment, talent, and future oncology success
• Map the delayed feedback structure of pharmaceutical R&D and explain how multi-year clinical-trial delays destabilize portfolio balancing loops
• Analyze why portfolio review and stage-gate balancing loops fail to correct pipeline concentration when feedback arrives a decade too late
• Apply open systems theory to understand how FDA signals, payer behavior, competitor moves, and capital markets reinforce therapeutic-area concentration
• Design interventions-protected pipeline floors, parallel early-stage investment, strategic acquisitions-that rebalance the portfolio without killing the blockbuster engine